You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API CAPECITABINE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing CAPECITABINE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Genentech Inc XELODA capecitabine 0004-1100 ANHYDROUS LACTOSE
Genentech Inc XELODA capecitabine 0004-1100 CELLULOSE, MICROCRYSTALLINE
Genentech Inc XELODA capecitabine 0004-1100 CROSCARMELLOSE SODIUM
Genentech Inc XELODA capecitabine 0004-1100 FERRIC OXIDE RED
Genentech Inc XELODA capecitabine 0004-1100 FERRIC OXIDE YELLOW
Genentech Inc XELODA capecitabine 0004-1100 HYPROMELLOSE 2208
Genentech Inc XELODA capecitabine 0004-1100 HYPROMELLOSE 2910
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing CAPECITABINE

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 FD&C BLUE NO. 2
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 HYPROMELLOSE
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271 MAGNESIUM STEARATE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for CAPECITABINE

Excipient focus: ANHYDROUS LACTOSE

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: HYPROMELLOSE

CAPECITABINE drug variants containing HYPROMELLOSE

Company Ingredient NDC
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271
Golden State Medical Supply Inc capecitabine 51407-095
State of Florida DOH Central Pharmacy capecitabine 53808-0411
Areva Pharmaceuticals capecitabine 59923-722
Sun Pharmaceutical Industries Inc capecitabine 62756-238
Ascend Laboratories LLC capecitabine 67877-458
Cipla USA Inc capecitabine 69097-949
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: HYPROMELLOSE 2208

Excipient focus: HYPROMELLOSE 2910

CAPECITABINE drug variants not containing HYPROMELLOSE 2910

Company Ingredient NDC
Hikma Pharmaceuticals USA Inc capecitabine 0054-0271
AvPAK capecitabine 50268-154
Golden State Medical Supply Inc capecitabine 51407-095
State of Florida DOH Central Pharmacy capecitabine 53808-0411
Physicians Total Care Inc capecitabine 54868-4143
Areva Pharmaceuticals capecitabine 59923-722
Sun Pharmaceutical Industries Inc capecitabine 62756-238
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: HYPROMELLOSES

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MICROCRYSTALLINE CELLULOSE 102

Excipient focus: MICROCRYSTALLINE CELLULOSE 112

Excipient focus: POLYDEXTROSE

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 1000

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRIACETIN

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group